

The potential for malignancy from atopic disorders and allergic inflammation: A systematic review and meta-analysis

Amanda B. Muir^{1,2}  | Kelly A. Whelan³ | Michael K. Dougherty⁴ | Bailey Aaron¹ | Brianna Navarre¹ | Seema S. Aceves⁵ | Evan S. Dellon⁴ | Elizabeth T. Jensen⁶

¹Division of Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia, Philadelphia, PA

²Department of Pediatrics, Perlman School of Medicine at the University of Pennsylvania, Philadelphia, PA

³Fels Institute for Cancer Research & Molecular Biology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA

⁴Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC

⁵Division of Allergy, Immunology, Department of Pediatrics, University of California San Diego and Rady Children's Hospital, San Diego, CA, USA

⁶Wake Forest University School of Medicine, Department of Epidemiology and Prevention, Winston-Salem, NC

Correspondence

Amanda B. Muir, Division of Gastroenterology, Perlman School of Medicine, University of Pennsylvania, Abramson Research Center, 3615 Civic Center Blvd 902E, Philadelphia, PA 19104-6160, USA.

Email: muira@email.chop.edu

Funding information

This study was supported by the following NIH Grants: K01DK103953 (KAW), K08DK106444 and R03DK118310 01A1 (ABM), T32 DK007634 (MD), CEGIR (U54 AI117804) (ABM, ESD), is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS, and is funded through collaboration between NIAID, NIDDK and NCATS. CEGIR is also supported by patient advocacy groups including APFED, CURED and EFC.

Abstract

Objective: While chronic inflammation is a well-established risk factor for malignancy, studies evaluating the relationship between allergic inflammation and cancer have revealed conflicting results. Here, we aimed to assess the association between allergic inflammation in the lung (asthma), skin (eczema) or oesophagus (eosinophilic oesophagitis; EoE) and cancer at the organ site.

Design: We conducted a systematic review of the literature to identify observational studies (case-control, cohort and cross-sectional) evaluating the association between asthma and lung cancer, eczema and skin cancer, or EoE and oesophageal cancer. Random-effects meta-analysis was performed to define pooled estimates of effects.

Data sources: PubMed, EMBASE and Web of Science.

Eligibility criteria for selection: Included studies evaluated the incidence of cancer.

Results: Thirty-two studies met the inclusion criteria, 27 in the lung, four in the skin and one in the oesophagus. Meta-analysis of the three studies with prospective data collection of asthma diagnosis revealed a positive association with incident lung cancer (OR 1.27, 95% CI 1.09-1.44); however, this result was not consistently supported by the larger dataset of retrospective studies (OR 1.37, 95% CI 0.90-1.83). Overall, studies in the lung displayed significant heterogeneity (I^2 98%, $P < .0001$), but no significant effect modification on the association between asthma and lung cancer was identified for the variables of sex, smoking or study design. Meta-analysis could not be applied to the four papers reviewed in the skin, but three suggested an association between eczema and non-melanoma skin cancer, while the remaining study failed to identify an association between melanoma and eczema. A single study meeting inclusion criteria showed no association between EoE and oesophageal malignancy.

Conclusions: The current data cannot exclude the possibility of an association between atopy and malignancy the lung, skin and oesophagus. The relationship between allergy and cancer should be explored further in prospective studies that any association identified between these conditions has the potential for significant public health implications.

1 | INTRODUCTION

Allergic disease is increasing in incidence worldwide and may manifest in different organs, including the lung, skin and gastrointestinal tract.^{1,2} Asthma, eczema and eosinophilic oesophagitis (EoE) cause chronic allergic inflammation of the lungs, skin and oesophagus, respectively. Allergic inflammation differs from autoimmune and infectious inflammation in that it tends to be driven by a T-helper two predominant inflammatory response (with interleukin 4, 5 and 13) and an eosinophil and mast cell predominance. While clinicians strive to identify and mitigate antigen exposures, and provide therapeutic interventions where necessary, the efficacy of such approaches is variable. As a result, atopic patients often experience long-standing inflammation. These challenges underscore the importance of understanding the natural history of allergic diseases and how they may influence tissue biology.

Chronic inflammation is a well-established risk factor for malignancy across tissue types. Mechanisms through which a persistent inflammatory microenvironment facilitates tumorigenesis include increased cell turnover, free radical production, diminished DNA repair capacity and stromal activation.³ In the gastrointestinal tract alone, ulcerative colitis has been associated with colon cancer, pancreatitis with pancreatic cancer and gastroesophageal reflux disease with oesophageal adenocarcinoma.^{4,5} Despite this paradigm of chronic inflammation as a tumour promoter, various studies have demonstrated a negative association between allergic inflammation and cancer risk, with enhanced immunosurveillance and activation of cellular protective mechanisms (eg apoptosis, senescence) suggested as proposed mechanisms through which malignant transformation is limited in atopic tissues.^{6,7} Additionally, allergic inflammation may be eosinophil-predominant, compared to other forms of chronic inflammation which are either mixed or neutrophil-predominant. The risk of allergic inflammation on cancer risk is not well established.

To assess the relationship between atopy and incidence of cancer specifically in the tissue in which allergic inflammation occurs, we performed a systematic review of literature analysing history of allergic conditions affecting the lung (asthma), skin (eczema) or oesophagus (eosinophilic oesophagitis; EoE) and incidence of malignancy in those organs. While few data exist regarding the risk of skin cancer and oesophageal cancer in patients with eczema and EoE, respectively, there is a breadth of literature regarding the association between asthma and lung cancer. We, therefore, performed meta-analysis of relevant publications, overall and also individually in retrospective and prospective studies, to synthesize the evidence for a relationship between asthma and lung cancer.

2 | METHODS

2.1 | Design

We conducted a systematic review of the literature to assess whether organ-specific atopy is associated with malignancy (PROSPERO

registration CRD42018092447). The data have been reported according to the PRISMA guidelines for systematic review and meta-analyses (Figure S1).

2.2 | Literature search

PubMed, EMBASE and Web of Science databases were systematically searched with the assistance of a library scientist using key words and MeSH terms for each organ (eg eosinophilic oesophagitis and oesophageal cancer). Included studies were English language, case-control, cohort and cross-sectional design studies. The final literature search was performed on 26 January 2018.

2.3 | Study selection

Primary exposures for each key question were the allergic conditions asthma, atopic dermatitis and EoE. Primary outcomes were incident lung cancer, skin cancer and oesophageal cancer, respectively. Diagnoses were accepted as presented in the original studies. Studies focused on populations at elevated cancer risk from non-tobacco toxin exposure (eg asbestos, coal) were excluded. Studies that failed to separate the allergic condition exposure in question from other comorbidities were excluded (eg co-association of asthma and hayfever with lung cancer). Studies that evaluated only cancer mortality (without separating cancer incidence) were excluded.

Two authors (ABM and KW) independently reviewed all abstracts to determine whether the study met study inclusion criteria. Differences were resolved by discussion, and any disagreement was resolved by consulting additional reviewers (ESD, ETJ), who made the final decision. Full texts of all studies selected were obtained for data extraction.

2.4 | Data extraction

Two authors (ABM and KW) independently extracted data from full-text articles. Details of the studies were documented in a standardized table, including the following data elements: first author, year, study design, sample size(s), measure obtained (eg odds ratio, hazard ratio, relative risk), effect estimates and potential for bias, including possible confounding factors.

2.5 | Risk of bias assessment

Quality assessment of all eligible articles was done by two authors (ABM and KW), with any differences discussed and resolved with a third author (MD). Study quality was assessed using the NIH National Heart, Lung, and Blood Institute Quality Assessment Tools (<https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>). Case control and cohort modules were utilized where appropriate.

2.6 | Statistical analyses

For comparisons where two or more studies reported a similar outcome and an odds ratio could be calculated from each, we estimated a pooled odds ratio using random-effects meta-analysis, according to the inverse-variance weighted method.⁸ For studies that only reported a standardized incidence ratio (SIR), we used the SIR to impute numbers of subjects with and without the outcome in question from a comparison group of equal size, allowing combination with other studies in a pooled odds ratio. The main analyses pooled adjusted odds ratios from each study, when these were provided. We also performed sensitivity analyses pooling the raw numbers from each study. The meta-analysis only examined odds ratios, either reported or calculated, but did not pool odds ratios with other measures (such as hazard or risk ratio). Primary analyses considered only those study estimates that accounted for latency of lung cancer diagnosis (excluding asthma diagnoses reported within 1-5 years of cancer diagnosis), to reduce protopathic bias due to misattribution of early pulmonary symptoms. A sensitivity analysis included all estimates extracted irrespective of whether the cancer diagnosis was made within 1-5 years of the diagnosis of the allergic disease. We assessed between-study heterogeneity visually using forest plots and quantitatively with the I-squared (I^2) statistic, which is the percentage of total variance from between-study rather than within-study variance.⁹ For each pooled effect, we estimated 95% confidence and predictive intervals, representing the confidence interval for the mean of the random-effects distribution and the range within which 95% of future study effects are predicted to fall, respectively.¹⁰ To explore causes of heterogeneity, we performed subgroup analyses according to study characteristics including sex, smoking status, study design, risk of bias and year of publication, when there were at least two studies in each subgroup. Specifically, we separated studies with data collected prospectively vs retrospectively when this affected the summary estimate. For asthma, where there were >10 studies assessing asthma in relation to lung cancer, funnel plots were examined visually for asymmetry suggestive of small-study effects (such as publication bias), supplemented with quantification by the Egger test.¹¹ If publication bias was detected, the "trim-and-fill" method was used to determine a random-effects summary estimate adjusted for publication bias.¹² All analyses were performed in Stata 14.2 (StataCorp, College Station, TX), with a significance threshold of a 2-sided $P < .05$.

3 | RESULTS

3.1 | Literature search results

Our initial literature search identified 3929 records. After excluding duplicates and studies that did not meet the defined inclusion criteria, 92 articles were subjected to full-text review, identifying 32

relevant studies: 27 in the lung, four in the skin and one in the oesophagus (Figure 1; Tables 1,2).

3.2 | Asthma and incidence of lung cancer


Twenty-seven studies of 939 248 unique asthmatic subjects examined the association of asthma with lung cancer incidence and were pooled using random-effects meta-analysis (Table 1). The majority of the studies (22) were case-control studies, and only three studies collected data prospectively.¹³⁻¹⁵ Asthma was associated with increased odds of incident lung cancer, but this was not statistically significant overall (OR 1.34, 95% CI 0.93-1.76, Figure 2) or in the subgroup of studies with retrospective data collection of asthma diagnosis (OR 1.37, 95% CI 0.90-1.83). The pooled estimate from the three prospective studies was significant due to less heterogeneity resulting in narrower confidence intervals, though with similar magnitude (OR 1.27, 95% CI 1.09-1.44). Heterogeneity resulted in a 95% predictive interval spanning the null in all analyses, however. Indeed, 15 of the 26 studies had confidence intervals either spanning the null^{13,14,16-26} or with a significant inverse association.²⁷ When restricting the analysis to studies that reported adjusted odds ratios (AORs), the magnitude of the association attenuated slightly and results were less heterogeneous (OR 1.19, 95% CI 0.99-1.38, I^2 47%, Figure S2). The associations were very similar for a variety of sensitivity analyses, including analyses pooling raw numbers of patients rather than aORs (OR 1.38, 95% CI 1.09-1.74, Figure S3) as well as analyses emphasizing non-latency-adjusted estimates along with either pooling AORs (OR 1.20, 95% CI 1.04-1.35) or pooling raw numbers of participants (OR 1.40, 95% CI 1.10-1.77) (Figures S4 and S5). In fact, accounting for latency did not significantly affect overall estimates ($P = .91$, Figure S4).

In subgroup analyses by patient characteristics, we emphasized meta-analytic estimates derived from raw numbers rather than adjusted odds ratios, since the reported aORs often adjusted for these factors already, by design. No significant effect modification was found for the effects of sex or smoking on the association between asthma and lung cancer in the main analyses (Figures 3 and 4, with sensitivity analyses using pooled aORs in Figures S6 and S7). For sex, this was true whether stratifying by studies that reported estimates by subgroups (Figure 3), or evaluating the effect of the percentage of male subjects in each study by meta-regression ($P = .46$). There were a greater number of studies including just women, which led to a very small, but statistically significant association between asthma and lung cancer in pooled estimates for females only, which was not significant in subgroups of only males (Figure 3). The association between asthma and lung cancer was not significantly different by smoking status either, whether stratifying by current smoking status (Figure 4A) or history of ever smoking (Figure 4B), or by meta-regression of percentage of never-smokers ($P = .62$). Due to the larger number of smokers, as well as greater cancer incidence in this population, the association between asthma and lung cancer was still observed in

Flow Chart of Searches Performed

FIGURE 1 Flow chart of searches performed

1. Eosinophilic Esophagitis and Esophageal Cancer
2. Eczema and Skin Cancer
3. Asthma and Lung Cancer



the smoking subgroup, but did not meet statistical significance in the subgroup of non-smokers (Figure 4).

The magnitude of the odds ratios was consistent across other sensitivity analyses of study characteristics as well. An analysis removing the four studies where control group numbers were imputed from SIRs^{14,28-30} reduced the overall power of the analysis without any change in the magnitude of the effect size (OR 1.32, 95% CI 0.85-1.79). Meta-regression did not reveal any statistically significant effect modification by study design (retrospectively vs prospectively collected data, $P = .68$) or year of publication ($P = .65$). Of the 26 studies included in any analysis, 10 were at low risk of bias, nine at medium and seven at high risk of bias (Table 1). There was a trend towards lower pooled aORs with decreasing risk

of bias, but this was not statistically significant ($P = .10$). A sensitivity analysis excluding those studies at high risk of bias somewhat attenuated the magnitude of the estimate, and with less heterogeneity, but with some loss in the precision of the estimate given the reduced sample (OR 1.17, 95% CI 0.99-1.36, Figure S8). There was statistically significant funnel plot asymmetry for the entire group of studies in the main analysis (Egger's test $P < .001$, Figure S9), but (atypically) with smaller studies showing smaller magnitudes of an association between asthma and lung cancer. This suggests the possibility that publication bias or other small-study effects could have biased the results towards the null. The pooled random-effects odds ratio adjusted for publication bias by the trim-and-fill method was 1.39 (95% CI 1.09-1.77, vs OR 1.34 for main effect,

TABLE 1 Characteristics of published studies on asthma and lung cancer

Author	Year	Study Type	Sex (M, F)	Smoking (S, NS, B, U)	Covariates	Latency Considered (Yes/No)	Total	Quality assessment
Alavanja et al	1992	Population-based case control	F	NS	Age, education, marital status, drivers status, healthcare finance registration, smoking history	Yes	2020	Fair
Boffetta et al	2002	Prospective population-based cohort	M, F	U	Duration of follow-up, calendar year at entry, age at entry, other diagnoses at index hospitalization, dept of index hospitalization, # of hospitalizations during 1st year of follow-up, presence of emphysema, chronic bronchitis, histological type of lung cancer	Yes	92986/std. pop.	Fair
Brenner et al	2001	Population-based case control	M, F	B	Active smoking and socio-economic status	Yes	2651	Good
Brownson et al	2000	Population-based case control	F	B	Pack-years of smoking	Yes	1376	Good
Colak et al	2015	Prospective cohort	M, F	B	Age; sex; BMI; allergy; familial predisposition for asthma; childhood asthma, hayfever, or eczema; use of asthma medication; occupational exposure to dust and/or fumes; daily exposure to passive smoking; leisure time physical activity; education; annual household income; and cumulative tobacco consumption, alcohol consumption, systolic and diastolic blood pressure, total cholesterol, LDL, HDL, triglycerides, use of cholesterol-lowering medication and presence of diabetes	No	94 079	Poor
Denholm et al	2014	Large international case-control consortium	M, F	B	Sex, age, centre, ever-employed in a high-risk occupation, education, smoking status, cigarette pack-years and time since quitting smoking.	Yes	27 684	Good
El-Zein et al (and Ramanakumar et al)	2010	Population-based case control	M	B	Smoking, asbestos, ancestry, silica—all included in regression models	Yes	1267	Fair
El-Zein et al	2014	Case control	M, F	B	Adjusted for age, sex (except in sex-specific analyses), education, respondent status, ethnocultural origin, fruit and vegetable consumption, and smoking (represented by the comprehensive smoking index). Lifetime occupational history; and history of 11 selected medical conditions among which were asthma, allergic eczema and hayfever.	Yes	2655	Good
Gabriel et al	1972	Case control	M	U	Allergy: hayfever, eczema, urticaria, food reactions, smoking status	No	300	Poor
Gonzales-Perez et al	2006	Cohort study with nested case control	M, F	B	Age, sex, calendar year, BMI, alcohol, smoking, prior comorbidities (cardiovascular disease, diabetes, osteoarthritis/rheumatoid arthritis), health services utilization, use of aspirin, NSAID, paracetamol	Yes	19 658	Good
Gorlova et al	2006	Case control	M, F	NS	Age, gender, ethnicity, income, years of education	Yes	522	Good
Huang et al (and Jian et al)	2015	Population-based cohort	M, F	U	Age, gender, low income, lung diseases, comorbidities, urbanization and geographic area	No	15 219 024	Poor
Ji et al	2009	Longitudinal cohort	M, F		5-year age (person-years calculated from the last hospitalization admission for asthma until diagnosis of cancer, death emigration of closing date), gender, period (5-year group), socio-economic class, residential area	Yes	140425/std pop	Poor

(Continues)

TABLE 1 (Continued)

Author	Year	Study Type	Sex (M, F)	Smoking (S, NS, B, U)	Covariates	Latency Considered (Yes/No)	Total	Quality assessment
Koshiol et al (total)	2009	Population-based case control	M, F	B	Smoking, other previous lung diseases and study design variables	Yes	3523	Good
Liang et al	2009	Case control	F	NS	Age, marital status, years of schooling, ethnicity, 5 y ago BMI, passive smoking exposure, coal fuel use, exposure to coal smoke and cooking fumes, history of mental trauma in last 20 y, lifetime exercise habits, family cancer history in 1st-degree relatives	Yes	505	Fair
Lim et al	2011	Case control	F	B	Age, history of cancer in first-degree relative, fruit and vegetable consumption, country of origin, dialect group, housing type, number of years in school, environmental tobacco exposure at home, environmental tobacco exposure at work and study	No	1808	Fair
Littman et al	2004	Prospective cohort	M, F	S	Sex and exposure cohort (female; male, in smoker cohort; male, in asbestos-exposed worker cohort), study arm (intervention or placebo), education, BMI, years smoked and years smoked squared, average number of cigarettes smoked per day and average number of cigarettes smoked per day squared, and all other lung diseases, and stratified by smoking status (former or current).	No	17 698	Poor
Mayne et al	1999	Population-based case control	M, F	NS	Years of schooling, cigarettes per day, lifetime passive smoke exposure, frequency of consumption of fresh fruit and vegetables, whole milk and supplemental vitamin E	Yes	874	Good
Osann et al	2000	Case control	F	B	Age, education, smoking	No	302	Fair
Pirie et al	2016	Cohort	F	NS	Age, oral contraceptive use, region, deprivation quintile, height	Yes	1.2 million	Good
Samet et al	1986	Case control	M, F	B	Tobacco use, residence history, occupational history, diet, passive exposure to tobacco smoke and certain occupational agents, history of respiratory diseases, personal history of physician-diagnosed chronic bronchitis, emphysema, asthma, tuberculosis and other chest illnesses	No	1314	Poor
Vena et al	1985	Case control	M, F	B	Age, smoking, lifetime history of asthma, hayfever, hives, eczema,	Yes	5225	Good
Vesterinen et al	1993	Cohort	M, F	U	Age, sex	Yes	77952/std pop	Fair
Wang et al	2009	Population-based control	F	B	Age, employment, total dish year, intake of yellow/orange/dark green veggies, intake of multivitamins	Yes	504	Fair
Wang et al	2006	Case control	M, F	B	Age, education, BMI, family history of cancer (1st degree), smoking status, alcohol consumption	No	4467	Fair
Wu et al	1995	Case control	F	NS	Adjusted for age, area, ethnicity or adjusted for age, area, ethnicity, education, exposure to tobacco during early life	No	1665	Fair
Wu et al	1988	Case control	F	B	Pack-years smoking, years since smoking stopped, depth of inhalation, adenocarcinoma	No	672	Poor

TABLE 2 Characteristics of published studies on eczema and skin cancer

Author	Year	Study Type	Control	Case	Total	Cancer Type	Covariates	Latency Considered (Yes/No)	Sex (M, F)	Odds Ratio	Confidence Interval	Quality Assessment
Cheng et al	2015	Case control	BCC: 251 SCC: 432	BCC: 375 SCC: 254	1312	Early-onset BCC and invasive SCC	Age, sex, smoking status, corticosteroid use, immunosuppressant drug use, organ transplantation, ultraviolet radiation therapy, number of lifetime painful sunburns, skin reaction to first hour of summer sun, solar elastosis, actinic keratosis, family history of keratinocyte cancer, recreation outdoors time, mole/freckles history, alcohol consumed per month, coffee/tea consumption, tanning lamp use, history of UV radiation therapy, history of radiation therapy	Yes	M, F	BCC: 0.77-1.52 SCC: 0.97-3.45 1.83	BCC: 0.77-3.01 SCC: 0.97-3.45	Fair
Dyer et al	2012	Cohort	1079	52	1131	BCC	Sex, age, education, BCCs/SCCs in prior 5 y, family history of skin cancer, history of eczema, smoking status (current/former), sunburn history, Use of 5-FU, ACE/ARB, history of warts, sun sensitivity, latitude of residence history, total occupational decades outdoors in sun history, vacation history, total recreational months, ethnicity of grandparents, days spent outside, sunscreen use	Yes	M, F	1.38	0.95-2.03	Fair
El-Zien	2010	Case control	512	94	606	Melanoma	Ancestry, sports/outdoor activities	Yes	M	0.64	0.2-2.2	Fair
Olesen et al (adults)	2005	Cohort	2014	16	2030	All keratinocyte cancers	N/A	Yes	M, F	2.4	1.4-3.9	Poor

Association of lung cancer incidence with asthma




FIGURE 2 Random-effects meta-analysis of association of lung cancer incidence and asthma, with 95% confidence interval (diamond) and estimated predictive interval (lines extending on either side of diamond). Forest plot is stratified by study design. Adjusted odds ratios were used if provided by original study, and otherwise calculated from raw numbers of the original study (and therefore crude, unadjusted). Estimates that accounted for latency between asthma and lung cancer diagnosis were selected when available. ES, estimate (here, adjusted odds ratio); CI, confidence interval

above), suggesting the contribution of small-study effects was minor.

3.3 | Eczema and incidence of skin cancer

In the skin, we identified four studies evaluating the relationship between eczema and cancer (Table 2). Three of these studies³¹⁻³³ reported a positive association between eczema and skin cancer. Olesen et al identified 16 skin cancers in a cohort study of 2030 adults from Denmark in which the expected incidence was 6.6 (SMR 2.4, 95% CI 1.4-3.9).³¹ Cancers in this cohort were equally distributed between both males and females as well as squamous cell carcinomas (SCC)

and basal cell carcinomas (BCC). Increased risk for skin cancer was statistically significant with follow-up of 5-9 years, but failed to show statistical significance for cancers diagnosed in the population with >10 years of follow-up. In an additional study, Dyer et al reported a non-statistically significant positive association between history of eczema alone and BCC risk (HRR 1.38, 95% CI: 0.95-2.03; $P = .095$).³² However, history of eczema was identified as an independent risk factor for developing BCC upon incorporation into a multivariate model adjusting for factors including age, 5-year history of skin cancer and family history of skin cancer (HRR 1.52, 95% CI 1.01-2.09; $P = .037$).³² A positive association between eczema and either SCC (OR 1.83, 95% CI 0.97-3.45) or early-onset BCC (OR 1.52, 95% CI 0.77-3.01) was identified by Cheng et al³³; however, these associations did not reach

Association of lung cancer incidence with asthma, by sex





FIGURE 3 Random-effects meta-analysis of association of lung cancer incidence and asthma, stratified by sex. The association of asthma with lung cancer was not significantly different by sex ($P = .46$). Meta-analytic estimates calculated from raw numbers, given that most adjusted odds ratios already adjusted for sex. Estimates accounting for latency were used when provided. OR, odds ratio; CI, confidence interval

statistical significance. Upon stratification by sex, men with a history of eczema displayed an increased risk of SCC (OR 3.5, 95% CI 1.33–11.15). By contrast, in women, neither a history of eczema nor allergy was associated with SCC (eczema: OR 0.95, 95% CI 0.35–2.57; allergy: OR 0.59, 95% CI 0.29–1.19). Both men (OR 2.02, 95% CI 0.61–6.72) and women (OR 1.59, 95% CI 0.66–3.80) exhibited a positive, but non-statistically significant association between history of eczema and BCC. Finally, in a cohort consisting of 94 Canadian men, El-Zein found no significant association between history of eczema and melanoma (OR 0.64, 95% CI 0.2–2.2).¹⁸ Two out of the three studies reporting a positive association between eczema and skin cancer were judged to be at medium risk of bias, and one, Olesen et al, was found to be at a high risk of bias due to failure to evaluate the effect of time or possible confounders, including sun exposure. Conversely, El-Zein et al was found to be at medium risk of bias due to failure to assess latency effects.

3.4 | EoE and risk of oesophageal cancer

Our literature search of PubMed, WOS and EMBASE revealed one paper that met our inclusion criteria in the oesophagus, Syed et al. There were two case series, Lipka et al and Straumann et al, which followed EoE patients for an average of 13.6 and 7.2 years, respectively.^{34,35} Lipka et al was a single-centre, retrospective case series, reporting no identification of oesophageal malignancy via endoscopy in 13 EoE patients followed up over a 13.6-year mean period (range 5–24 years). Additionally, while 50% of EoE patients exhibited Barrett's oesophagus, the premalignant precursor to oesophageal adenocarcinoma, dysplasia was not detected upon histological review. Straumann et al prospectively followed 30 adults with EoE for 11.5 years and found that none of these patients developed malignancy.

Association of lung cancer incidence with asthma, by smoking history



Association of lung cancer incidence with asthma, by smoking history




FIGURE 4 Random-effects meta-analysis of association of lung cancer incidence and asthma, stratified by inclusion of any current smokers (A) or any ever-smokers (B). Meta-analytic estimates calculated from raw numbers, given that most adjusted odds ratios already adjusted for smoking. OR, odds ratio; CI, confidence interval

The study by Syed et al was a cross-sectional population-based study utilizing an administrative database³⁶ with over 340 hospitals and 22 major healthcare systems participating. With over 27 million patients, 0.02% had a diagnosis of EoE. None of these EoE patients had documentation of a diagnosis code for comorbid oesophageal cancer. A limitation of this study was that only 5 years of data were available for these patients, which may not be a long enough time of exposure for malignant transformation.

4 | DISCUSSION

The current study provides a comprehensive evaluation of data regarding asthma, eczema and EoE, and their association with cancer risk in the affected organ. In contrast to the skin and oesophagus, where few studies have been conducted to assess associations between allergy and organ-specific malignancy, numerous case-control and cohort studies have evaluated the association between asthma and cancer in the lung. Meta-analysis of these data revealed an increase in lung cancer risk in asthma patients that was significant when examining three studies with prospective collection of asthma diagnosis, but that was not consistently supported when evaluating either retrospective studies alone or the collective dataset. While at these differences with regard to data significance may be a result of decreased heterogeneity in the limited dataset provided by the prospective studies, these findings support the need additional studies with prospective collection of allergy diagnoses to further investigate the relationship between atopy and cancer. Notably, the positive association between asthma and lung cancer risk remained

consistent upon sub-analyses for effects of sex and smoking status. Geographic location and distribution of histologic lung cancer subtypes represent two potential sources of heterogeneity among these studies, and there were no studies with eosinophilic or neutrophilic asthma specifically assessed. A limitation of the body of evidence on atopic disease and organ-specific cancer is the potential for bias. In those studies using surveys to ascertain past medical histories from cases and controls,^{13-16,18-23,25-27,37-43} there is a potential for recall bias. Additionally, the temporality of atopic disease state and cancer is difficult to ascertain. Similarly, depending on duration of atopy and treatment efficacy, risk of cancer could differ. Risk of cancer in the setting of inflammatory diseases with cancer predisposition, including pancreatitis, ulcerative colitis and gastroesophageal reflux disease, is dependent on disease duration. While not all studies evaluated for duration of illness prior to onset of malignancy, we did make note of this in our systematic review. In the case of asthma, other meta-analyses have shown increased risk of lung cancer diagnosis in the 2 years following the diagnosis of asthma and no increase in the population with >10 years of asthma.⁴⁴ This may signify ascertainment bias, where lung cancer cases are identified due to increased healthcare surveillance at the time of asthma diagnosis. Additionally, eosinophilic asthma has been recently identified as an important subtype with different treatment algorithms. The studies we identified did not stratify by peripheral eosinophil count or eosinophilic asthma status, and it would be interesting to determine this risk in this purely allergic subpopulation.

In evaluating the association between eczema and skin cancer, our literature review identified only four studies meeting our inclusion criteria, each reporting different combinations of skin cancer subtypes

which precluded meta-analysis. Three of these studies identified increased skin cancer risk in eczema patients (two of which were not statistically significant), while the fourth failed to define any association between eczema and melanoma. In the study by Cheng et al, the positive association between eczema and skin cancer was present in both early-onset basal and invasive squamous cell carcinoma, while subtype-specific effects were not explored in the two other studies identifying increased cancer risk in eczema patients.³³ The study by El-Zein et al found no evidence of an association between eczema and melanoma; however, given that other skin cancer types were not evaluated, the potential remains that eczema may differentially influence specific histologic subtypes of skin cancer.¹⁸ Of these four studies, only that performed by Olesen et al included a primary diagnosis of eczema as an inclusion criterion. While this may alleviate concerns of recall bias, it also raises the potential for detection bias, as patients with eczema have an increased likelihood of undergoing clinical skin examinations during which cancer and pre-cancerous lesions may be detected. Importantly, as latency exclusion was not utilized in any of the four studies that met inclusion criteria in the skin, there exists the potential for misdiagnosis of eczema occurring close to the time cancer diagnosis. Failure to control for severity of atopic inflammation represented in these four studies represents an additional source of heterogeneity. While it is possible that control of atopic dermatitis inflammation could reduce subsequent cancer risk, as is the case for inflammatory conditions such as ulcerative colitis,⁴⁵ careful consideration must be given with regard to the agents used to alleviate allergic responses as links between several therapies and increased malignancy rates have been identified. For example, calcineurin inhibitors which are used topically to treat eczema have been associated with increased cancer risk in various organs, including the skin.⁴⁶⁻⁴⁸ Additionally, the FDA has raised concerns regarding increased cancer rates in patients treated with the anti-IgE antibody omalizumab. Although several studies failed to validate such concerns,^{49,50} further investigations are warranted.

While the relationship between EoE and oesophageal cancer is only beginning to be explored, such investigations may be particularly valuable for physicians who remain hesitant to treat asymptomatic EoE patients given the high burden of therapy for treatment of EoE^{51,52} and the fact that it is widely believed that EoE does not contribute to increased risk of malignant transformation. Supporting this notion, Lipka and Straumann et al both failed to detect oesophageal malignancy in small ($n = 30$ and 13 , respectively) EoE patient cohorts.^{34,35} The large cross-sectional population-based study by Syed et al revealed that in 5370 EoE patients evaluated, not a single case of oesophageal malignancy was documented over a 5-year period.³⁶ Limitations for these studies include inability to examine sex-specific effects, follow-up periods that are short with regard to cancer development, which occurs over decades, and lack of reporting on the histopathologic subtype of oesophageal malignancy being detected. While malignancy was not detected in EoE patients in the three studies described herein, eosinophils have been detected in oesophageal cancer lesions,^{53,54} and patients with oesophageal cancer often present with symptoms that are prevalent in EoE, including

dysphagia.⁵⁵ Given that EoE has only been characterized as distinct disease entity in the past two decades, it is possible that undiagnosed EoE cases may have influenced carcinogenesis in the oesophagus. Several studies have reported oesophageal granular cell tumours in EoE patients^{56,57}; however, such reports were excluded from the current analysis as these lesions are generally benign and of neuroendocrine origin. Nevertheless, the relationship between EoE and granular cell tumours would merit future assessment to determine whether there is a true association or whether it is incidental.

The strengths of the current study included its rigorous systematic review methods conforming to current guidelines, and its large sample size with nearly one million cases of lung cancer evaluated, allowing for evaluation of both smoking and sex differences within the studies. There were limitations in our ability to fully understand allergic inflammation and cancer risk in the skin and oesophagus due to lack of studies in this area. There is a great need to further understand the consequences of long-term eosinophilic inflammation in the oesophagus. EoE diagnosis is often delayed⁵⁸ and treatment response rates are low; therefore, many patients experience ongoing inflammation despite attempts at therapy.⁵⁹ Recently, developed in vitro and ex vivo tissue engineering strategies, such as oesophageal organoids, offer the unique ability to culture differentiated oesophageal epithelia with eosinophils for prolonged periods.^{60,61} These experiments may provide further better understanding of the mucosal stress responses and the evolution of carcinogenesis in the oesophagus.

As allergic disorders increase in incidence, it is important that we consider the long-term effects of allergic inflammation. The current study indicates some weak associations between allergic inflammation (eg asthma and eczema) and carcinogenesis within the organ in which they occur; however, heterogeneity and potential for confounding in the available literature preclude firm conclusions on the presence of such associations. This review highlights the need for future prospective cohort studies, with careful consideration for duration of allergic disease, type of inflammation, medication usage, success of treatment and disease activity control, and well-defined outcomes related to malignancy to elucidate the clinical impact of the complex interplay between chronic inflammation and carcinogenesis. Such studies will provide population-based data that will inform our understanding of how allergic inflammation influences carcinogenesis and may have critical implications for cancer prevention and therapy.

CONFLICT OF INTEREST

The authors have nothing to declare.

ORCID

Amanda B. Muir  <https://orcid.org/0000-0003-2616-7063>

REFERENCES

1. Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. *World Allergy Organ J.* 2014;7:12-13.
2. Prescott SL, Pawankar R, Allen KJ, et al. A global survey of changing patterns of food allergy burden in children. *World Allergy Organ J.* 2013;6:21-12.

3. Coussens LM, Werb Z. Inflammation and cancer. *Nature*. 2002;420:860-867.
4. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. *Am J Physiol Gastrointest Liver Physiol*. 2004;287:G7-17.
5. Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. *JAMA*. 2002;287:1972-1981.
6. Profet M. The function of allergy: immunological defense against toxins. *Q Rev Biol*. 1991;66:23-62.
7. Sherman PW, Holland E, Sherman JS. Allergies: their role in cancer prevention. *Q Rev Biol*. 2008;83:339-362.
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7:177-188.
9. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327:557-560.
10. Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ*. 2011;342:d549-d549.
11. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315:629-634.
12. Duval S, Tweedie R. A Nonparametric, "Trim and Fill" Method of Accounting for Publication Bias in Meta-Analysis. *J Am Stat Assoc*. 2000;95:89.
13. Çolak Y, Afzal S, Nordestgaard BG, et al. Characteristics and Prognosis of Never-Smokers and Smokers with Asthma in the Copenhagen General Population Study. A Prospective Cohort Study. *Am J Respir Crit Care Med*. 2015;192:172-181.
14. Littman AJ, Thornquist MD, White E, et al. Prior lung disease and risk of lung cancer in a large prospective study. *Cancer Causes Control*. 2004;15:819-827.
15. Pirie K, Peto R, Green J, et al. Lung cancer in never smokers in the UK Million Women Study. *Int J Cancer*. 2016;139:347-354.
16. Gabriel R, Dudley BM, Alexander WD. Lung cancer and allergy. *Br J Clin Pract*. 1972;26:202-204.
17. El-Zein M, Parent M-E, Siemiatycki J, et al. History of allergic diseases and lung cancer risk. *Ann Allergy Asthma Immunol*. 2014;112:230-236.
18. El-Zein M, Parent M-E, Kâ K, et al. History of asthma or eczema and cancer risk among men: a population-based case-control study in Montreal, Quebec, Canada. *Ann Allergy Asthma Immunol*. 2010;104:378-384.
19. Koshiol J, Rotunno M, Consonni D, et al. Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study. Vij N, ed. *PLoS ONE*. 2009;4:e7380.
20. Brownson RC, Alavanja MC. Previous lung disease and lung cancer risk among women (United States). *Cancer Causes Control*. 2000;11:853-858.
21. Alavanja MC, Brownson RC, Boice JD, et al. Preexisting lung disease and lung cancer among nonsmoking women. *Am J Epidemiol*. 1992;136:623-632.
22. Wu AH, Yu MC, Thomas DC, et al. Personal and family history of lung disease as risk factors for adenocarcinoma of the lung. *Cancer Res*. 1988;48:7279-7284.
23. Mayne ST, Buenconsejo J, Janerich DT. Previous lung disease and risk of lung cancer among men and women nonsmokers. *Am J Epidemiol*. 1999;149:13-20.
24. Osann KE, Lowery JT, Schell MJ. Small cell lung cancer in women: risk associated with smoking, prior respiratory disease, and occupation. *Lung Cancer*. 2000;28:1-10.
25. Wang H, Rothenbacher D, Löw M, et al. Atopic diseases, immunoglobulin E and risk of cancer of the prostate, breast, lung and colorectum. *Int J Cancer*. 2006;119:695-701.
26. Liang H, Guan P, Yin Z, et al. Risk of Lung Cancer following Nonmalignant Respiratory Conditions among Nonsmoking Women Living in Shenyang, Northeast China. *J Womens Health (Larchmt)*. 2009;18:1989-1995.
27. Denholm R, Schüz J, Straif K, et al. Is previous respiratory disease a risk factor for lung cancer? *Am J Respir Crit Care Med*. 2014;190:549-559.
28. Vesterinen E, Pukkala E, Timonen T, et al. Cancer incidence among 78,000 asthmatic patients. *Int J Epidemiol*. 1993;22:976-982.
29. Ji J, Shu X, Li X, et al. Cancer risk in hospitalised asthma patients. *Br J Cancer*. 2009;100:829-833.
30. Boffetta P, Ye W, Boman G, et al. Lung cancer risk in a population-based cohort of patients hospitalized for asthma in Sweden. *Eur Respir J*. 2002;19:127-133.
31. Olesen AB, Engholm G, Storm HH, et al. The risk of cancer among patients previously hospitalized for atopic dermatitis. *J Invest Dermatol*. 2005;125:445-449.
32. Dyer RK, Weinstock MA, Cohen TSD, et al. Predictors of basal cell carcinoma in high-risk patients in the VATTC (VA Topical Tretinoin Chemoprevention) trial. *J Invest Dermatol*. 2012;132:2544-2551.
33. Cheng J, Zens MS, Duell E, et al. History of allergy and atopic dermatitis in relation to squamous cell and Basal cell carcinoma of the skin. *Cancer Epidemiol Biomarkers Prev*. 2015;24:749-754.
34. Lipka S, Keshishian J, Boyce HW, et al. The natural history of steroid-naïve eosinophilic esophagitis in adults treated with endoscopic dilation and proton pump inhibitor therapy over a mean duration of nearly 14 years. *Gastrointest Endosc*. 2014;80:592-598.
35. Straumann A, Spichtin H-P, Grize L, et al. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. *Gastroenterology*. 2003;125:1660-1669.
36. Syed A, Maradey-Romero C, Fass R. The relationship between eosinophilic esophagitis and esophageal cancer. *Dis Esophagus*. 2017;30:1-5.
37. Vena JE, Bona JR, Byers TE, et al. Allergy-related diseases and cancer: an inverse association. *Am J Epidemiol*. 1985;122:66-74.
38. Samet JM, Humble CG, Pathak DR. Personal and family history of respiratory disease and lung cancer risk. *Am Rev Respir Dis*. 1986;134:466-470.
39. Gorlova OY, Zhang Y, Schabath MB, et al. Never smokers and lung cancer risk: a case-control study of epidemiological factors. *Int J Cancer*. 2006;118:1798-1804.
40. Wang X-R, Yu ITS, Chiu YL, et al. Previous pulmonary disease and family cancer history increase the risk of lung cancer among Hong Kong women. *Cancer Causes Control*. 2009;20:757-763.
41. Sherrill JD, Kc K, Wu D, et al. Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis. *Mucosal Immunol*. 2014;7:718-729.
42. Lim W-Y, Chen Y, Ali SM, et al. Polymorphisms in inflammatory pathway genes, host factors and lung cancer risk in Chinese female never-smokers. *Carcinogenesis*. 2011;32:522-529.
43. Brenner AV, Wang Z, Kleinerman RA, et al. Previous pulmonary diseases and risk of lung cancer in Gansu Province, China. *Int J Epidemiol*. 2001;30:118-124.
44. Rosenberger A, Bickeböller H, McCormack V, et al. Asthma and lung cancer risk: a systematic investigation by the International Lung Cancer Consortium. *Carcinogenesis*. 2012;33:587-597.
45. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. *Clin Gastroenterol Hepatol*. 2012;10:639-645.
46. Castellsague J, Kuiper JG, Pottegård A, et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study). *Clin Epidemiol*. 2018;10:299-310.
47. Hui RL, Lide W, Chan J, et al. Association between exposure to topical tacrolimus or pimecrolimus and cancers. *Ann Pharmacother*. 2009;43:1956-1963.

48. Arellano FM, Arana A, Wentworth CE, et al. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. *J Allergy Clin Immunol*. 2009;123:1111-1116.e13.
49. Johnston A, Smith C, Zheng C, et al. Influence of prolonged treatment with omalizumab on the development of solid epithelial cancer in patients with atopic asthma and chronic idiopathic urticaria: A systematic review and meta-analysis. *Clin Exp Allergy*. 2019;27:66.
50. Burns SO, Plagnol V, Gutierrez BM, et al. Immunodeficiency and disseminated mycobacterial infection associated with homozygous nonsense mutation of IKK β . *J Allergy Clin Immunol*. 2014;134:215-218.
51. Jensen ET, Kappelman MD, Martin CF, et al. Health-care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States. *Am J Gastroenterol*. 2015;110:626-632.
52. Muir A, Moore H, Spergel J. To treat or not to treat: The minimally symptomatic EoE patient. *Ann Allergy Asthma Immunol*; 2018.
53. Ishibashi S, Ohashi Y, Suzuki T, et al. Tumor-associated tissue eosinophilia in human esophageal squamous cell carcinoma. *Anticancer Res*. 2006;26:1419-1424.
54. Ohashi Y, Ishibashi S, Suzuki T, et al. Significance of tumor associated tissue eosinophilia and other inflammatory cell infiltrate in early esophageal squamous cell carcinoma. *Anticancer Res*. 2000;20:3025-3030.
55. Rustgi A, El-Serag HB. Esophageal carcinoma. *N Engl J Med*. 2015;372:1472-1473.
56. Nojkov B, Amin M, Ghaith G, et al. A statistically significant association between esophageal granular cell tumors and eosinophilic esophagitis: A 16-year analysis at two large hospitals of 167,434 EGDs. *Dig Dis Sci*. 2017;62:3517-3524.
57. Lucendo AJ, De Rezende L, Martín-Plaza J, et al. Esophageal granular cell tumor and eosinophilic esophagitis: two interesting entities identified in the same patient. *Case Rep Gastroenterol*. 2008;2:33-39.
58. Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. *Gastroenterology*. 2013;145(1230-6):e1-2.
59. Dellon ES. Management of refractory eosinophilic oesophagitis. *Nat Rev Gastroenterol Hepatol*. 2017;14:479-490.
60. Kasagi Y, Chandramouleeswaran PM, Whelan KA, et al. The esophageal organoid system reveals functional interplay between notch and cytokines in reactive epithelial changes. *Cell Mol Gastroenterol Hepatol*. 2018;5:333-352.
61. Whelan KA, Muir AB, Nakagawa H. Esophageal 3D Culture Systems as Modeling Tools in Esophageal Epithelial Pathobiology and Personalized Medicine. *Cell Mol Gastroenterol Hepatol*. 2018;5:461-478.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Muir AB, Whelan KA, Dougherty MK, et al. The potential for malignancy from atopic disorders and allergic inflammation: A systematic review and meta-analysis. *Clin Exp Allergy*. 2020;50:147-159. <https://doi.org/10.1111/cea.13537>



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5-6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5-6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6-8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8-9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	8-10




PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	11
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	10
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	Figure 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Table 1
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Table 1
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	S5
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	11
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	10-12
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	12
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	14
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	15
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	17-18
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	2

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097


For more information, visit: www.prisma-statement.org.

Association of lung cancer incidence with asthma




Supplemental Figure S2. Random-effects meta-analysis of association of lung cancer incidence and asthma, with 95% confidence interval (diamond) and estimated predictive interval (lines extending on either side of diamond). These are the same study estimates as in Figure 2, but the forest plot is stratified by whether odds ratios were adjusted by original study, or calculated from raw numbers of the original study (and therefore crude, unadjusted). Estimates that accounted for latency between asthma and lung cancer diagnosis were selected when available. ES, estimate (here, adjusted odds ratio); CI, confidence interval.

Association of lung cancer incidence with asthma




Supplemental Figure S3. Random-effects meta-analysis of association of lung cancer incidence and asthma, with 95% confidence interval (diamond) and estimated predictive interval (lines extending on either side of diamond). Meta-analytic estimates calculated from raw numbers rather than adjusted odds ratios, and stratified by study design. Estimates that accounted for latency between asthma and lung cancer diagnosis were selected when available. ES, estimate (here, adjusted odds ratio); CI, confidence interval.

Association of lung cancer incidence with asthma




Supplemental Figure S4. Random-effects meta-analysis of association of lung cancer incidence and asthma, with 95% confidence interval (diamond), by whether latency was accounted for. Meta-analytic estimates calculated from adjusted odds ratios, and the plot only includes studies that provided these. Studies that reported latency-corrected and latency-uncorrected figures contribute each, so there is no overall summary estimate. The difference between the subgroups was non-significant in meta-regression ($p=0.91$). ES, estimate (here, adjusted odds ratio); CI, confidence interval

Association of lung cancer incidence with asthma




Supplemental Figure S5. Random-effects meta-analysis of association of lung cancer incidence and asthma, with 95% confidence interval (diamond), by whether latency was accounted for. Meta-analytic estimates calculated from raw numbers of participants. Studies that reported latency-corrected and latency-uncorrected figures contribute each, so there is no overall summary estimate. The difference between the subgroups was non-significant (p=0.84). OR, odds ratio; CI, confidence interval.

Association of lung cancer incidence with asthma, by sex




Supplemental Figure S6. Random-effects meta-analysis of association of lung cancer incidence and asthma, stratified by sex. The association of asthma with lung cancer was not statistically significantly different by sex ($p=0.14$). Meta-analytic estimates calculated from pooled odds ratios, using adjusted odds ratios and those that accounted for latency when provided, but many of the adjusted odds ratios already adjusted for sex. ES, estimate (here, adjusted odds ratio); CI, confidence interval.

Association of lung cancer incidence with asthma, by risk of bias




Supplemental Figure S8. Random-effects meta-analysis of association of lung cancer incidence and asthma, stratified by risk of bias, and limited to studies at medium or low risk of bias. The association of asthma with lung cancer was not statistically significantly different by study risk of bias ($p=0.69$). Meta-analytic estimates calculated from pooled odds ratios, using adjusted odds ratios and those that accounted for latency when provided. ES, estimate (here, adjusted odds ratio); CI, confidence interval.


Association of lung cancer incidence with asthma, by smoking history



Association of lung cancer incidence with asthma, by smoking history



Supplemental Figure S7. Random-effects meta-analysis of association of lung cancer incidence and asthma, stratified by inclusion of any current smokers (**A**) or any ever-smokers (**B**). Meta-analytic estimates from pooled odds ratios, including adjusted odds ratios when provided, noting that many of these already adjusted for smoking. ES, estimate (here, adjusted odds ratio); CI, confidence interval.



Supplemental Figure S9. Funnel plot of log odds ratio vs standard error of the log odds ratio, with 95% pseudoconfidence limits. The x-axis is subsequently exponentiated to back-transform to an odds ratio. There is statistically significant asymmetry (Egger's test $p < 0.001$), suggesting the presence of small-study effects, possibly biasing the effect estimate negatively towards from the null.